Skip to Main Content

And so, the morning after has arrived. Nothing like a surprise, yes? Well, the world will continue to spin no matter what, so adjust your seat belt accordingly. If nothing else, this calls for a few cups of stimulation. Remember, no prescription is required. Meanwhile, there is much to do. So here is the menu of tidbits to help you along. Hope your day goes well and your crystal ball does not fog up …

Pharmaceutical stocks are doing well this morning as investors bet that a President Trump is not as likely to take tough action on drug pricing, Reuters suggests. The betting was buoyed still more as news that a California ballot initiative aimed at reining in rising prescription drug prices was headed for defeat, according to a state website. Shares in major European drug makers were up between 2 and 6 percent, but STAT says anxiety remains.


The Department of Health and Human Services watchdog warned the Centers for Medicare and Medicaid Services in 2009 that Mylan misclassified EpiPen under the Medicaid Drug Rebate Program, Senator Chuck Grassley (R-Iowa) wrote in a letter. Mylan agreed to pay $465 million for failing to pay sufficient rebates to Medicaid for several years, but the disclosure raises questions as to why the misclassification persisted until recently.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Volkow is obviously in the tank for those who believe that addicts can “control” their addiction. She is under the misapprehension that an addict can titrate down their daily use by 75% when in fact addiction itself is defined by loses of control of the substance of choice. Total abstinence is not a “gigantic bar”. Walk into any NA/AA meeting to see for yourself. Those who see abstinence as a gigantic bar are either not ready or not willing to take the steps required to be clean and sober.

Comments are closed.